Generic placeholder image

Cardiovascular & Hematological Agents in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1871-5257
ISSN (Online): 1875-6182

Perspective

Ferroptosis Inhibitors as New Therapeutic Insights into Radiation-Induced Heart Disease

Author(s): Soghra Farzipour, Fatemeh Jalali, Maryam Alvandi and Zahra Shaghaghi*

Volume 21, Issue 1, 2023

Published on: 26 August, 2022

Page: [2 - 9] Pages: 8

DOI: 10.2174/1871525720666220713101736

Abstract

Radiation-induced heart disease (RIHD) is a significant cause of morbidity in breast and other mediastinal cancers. The many molecular and cellular patho-mechanisms that have a role in RIHD are not completely understood. Endothelial injury, oxidative stress, and inflammation, as well as endoplasmic reticulum and mitochondrial damage, are considered the primary causes of RIHD. Ferroptosis is a newly discovered type of cell death that results from irondependent lipid peroxide accumulation. As ferroptosis plays an important role in the pathogenesis of cardiovascular diseases, it seems that it has a significant effect on RIHD. It was recently shown that ionizing radiation (IR) generates severe ferroptosis, which is a critical component of Radiotherapy-mediated normal cell toxicity. These findings support the use of a ferroptosis inhibitor to reduce RIHD. In this perspective review, we summarize the role of ferroptosis in pathogens of cardiovascular disease and radiation toxicity, and we will introduce ferroptosis inhibitors as a new strategy to prevent or reduce RIHD.

Keywords: Ferroptosis, radiotherapy, heart disease, radioprotective, ferrostatin-1, ferroptosis inhibitor.

« Previous

© 2023 Bentham Science Publishers | Privacy Policy